Adagene (ADAG) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

ADAG · Stock Price

USD 3.58+1.98 (+123.75%)

Market Cap: $239.2M

Historical price data

Market Cap: $239.2MPipeline: 9 drugsFounded: 2011Employees: 100-250HQ: Suzhou, China

Overview

Adagene's mission is to transform antibody drug discovery and development through its proprietary AI-powered Dynamic Precision Library (DPL) platform. The company has achieved significant validation through strategic collaborations with global pharmaceutical partners and has advanced a pipeline of nine candidates, including its lead SAFEbody-masked anti-CTLA-4 program, ADG126, which has shown a compelling clinical safety profile. Its strategy focuses on leveraging computational design to create precision biologics with enhanced therapeutic indices, aiming to deliver first- or best-in-class therapies in oncology while monetizing its platform through partnerships.

Oncology

Technology Platform

The Dynamic Precision Library (DPL) platform integrates computational immunology, AI, and machine learning to design novel antibodies. Its core modules include NEObody for novel epitope targeting, SAFEbody for conditional activation, and POWERbody for enhanced immune cell engagement.

Pipeline

9

9 drugs in pipeline

Drug	Indication	Stage
ADG126 + Pembrolizumab	Locally Advanced Colorectal Cancer	Phase 2
ADG106 injection + PD-1 antibody injection	Solid Tumor	Phase 1/2
ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel	HER2-negative Breast Cancer	Phase 1/2
ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106	Advanced/Metastatic Solid Tumors	Phase 1/2
ADG116	Solid Tumor	Phase 1

Opportunities

The primary opportunity lies in validating its SAFEbody-masked anti-CTLA-4 therapy, ADG126, which could capture significant market share by offering a safer, more effective alternative to existing toxic checkpoint inhibitors.

Success would also massively de-risk and increase the value of its entire platform for creating conditionally activated versions of other potent but toxic immuno-oncology targets and modalities.

Risk Factors

The key risks are clinical failure of its lead asset, ADG126, which would undermine its core technology thesis; financial instability due to its pre-revenue status and low market cap, necessitating dilutive financing; and intense competition from other next-generation CTLA-4 programs and AI-driven discovery platforms.

Competitive Landscape

Adagene's platform competes with other AI/ML drug discovery companies like AbCellera and Absci. Its lead clinical candidate, ADG126, faces direct competition from next-generation CTLA-4 inhibitors in development by BioNTech and AstraZeneca, which also aim to improve safety. Differentiation will be determined by head-to-head clinical data on safety and efficacy profiles.

More companies in China →